Metabolism inhibitors for cancer treatment
Small molecule inhibitors of dihydroorotate dehydrogenase (DHODH), a metabolic vulnerability in oncogene addicted cancer
We are targeting metabolic vulnerabilities in oncogene addicted cancer
Read more
Our Team
We assembled a team with deep expertise in oncology venture development to execute on our mission to exploit metabolic vulnerabilities in oncogene addicted cancers. The team previously navigated the development of multiple oncology drugs from preclinical stage to the market. In particular, the team successfully developed the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib for mantle cell lymphoma and chronic lymphocytic leukemia.
Our People